title: Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-kappa B (p50-p65) and retinoic acid receptor beta-retinoid X receptor beta heterodimers.
abstract: Retinoic acid (RA) treatment of human embryonal carcinoma (EC) NTera-2 (NT2) cells induces expression of major histocompatibility complex (MHC) class I and beta-2 microglobulin surface molecules. We found that this induction was accompanied by increased levels of MHC class I mRNA, which was attributable to the activation of the two conserved upstream enhancers, region I (NF-kappa B like) and region II. This activation coincided with the induction of nuclear factor binding activities specific for the two enhancers. Region I binding activity was not present in undifferentiated NT2 cells, but binding of an NF-kappa B heterodimer, p50-p65, was induced following RA treatment. The p50-p65 heterodimer was produced as a result of de novo induction of p50 and p65 mRNAs. Region II binding activity was present in undifferentiated cells at low levels but was greatly augmented by RA treatment because of activation of a nuclear hormone receptor heterodimer composed of the retinoid X receptor (RXR beta) and the RA receptor (RAR beta). The RXR beta-RAR beta heterodimer also bound RA responsive elements present in other genes which are likely to be involved in RA triggering of EC cell differentiation. Furthermore, transfection of p50 and p65 into undifferentiated NT2 cells synergistically activated region I-dependent MHC class I reporter activity. A similar increase in MHC class I reporter activity was demonstrated by cotransfection of RXR beta and RAR beta. These data show that following RA treatment, heterodimers of two transcription factor families are induced to bind to the MHC enhancers, which at least partly accounts for RA induction of MHC class I expression in NT2 EC cells.
authors.affiliation: Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.
authors.forename: J H
authors.initials: JH
authors.lastname: Segars
authors.forename: T
authors.initials: T
authors.lastname: Nagata
authors.forename: V
authors.initials: V
authors.lastname: Bours
authors.forename: J A
authors.initials: JA
authors.lastname: Medin
authors.forename: G
authors.initials: G
authors.lastname: Franzoso
authors.forename: J C
authors.initials: JC
authors.lastname: Blanco
authors.forename: P D
authors.initials: PD
authors.lastname: Drew
authors.forename: K G
authors.initials: KG
authors.lastname: Becker
authors.forename: J
authors.initials: J
authors.lastname: An
authors.forename: T
authors.initials: T
authors.lastname: Tang
mesh_terms: D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D004247:DNA; D054278:Embryonal Carcinoma Stem Cells; D005786:Gene Expression Regulation; D005805:Genes, MHC Class I; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D016328:NF-kappa B / Q000378:metabolism*; D014411:Neoplastic Stem Cells; D011401:Promoter Regions, Genetic; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D018168:Receptors, Retinoic Acid / Q000378:metabolism*; D047488:Retinoid X Receptors; D014157:Transcription Factors; D014162:Transfection; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D016328:NF-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D014157:Transcription Factors; D014212:Tretinoin; D004247:DNA